Hematopoietic stem cells (HSCs) continuously replenish all blood cell types through a series of 24 differentiation steps that involve the generation of lineage-committed progenitors as well as necessary 25 expansion due to repeated cell divisions. However, whether cell division in HSCs precedes differentiation 26 is unclear. To this end, we used an HSC cell tracing approach and Ki67 RFP knock-in mice to assess 27 simultaneously divisional history, cell cycle progression, and differentiation of adult HSCs in vivo. Our 28 results reveal that HSCs are able to differentiate into restricted progenitors, especially common myeloid 29 progenitors, restricted megakaryocyte-erythroid progenitors (PreMEs) and pre-megakaryocyte progenitors 30 (PreMegs), without undergoing cell division and even before entering the S phase of the cell cycle. 31
Summary 23
Hematopoietic stem cells (HSCs) continuously replenish all blood cell types through a series of 24 differentiation steps that involve the generation of lineage-committed progenitors as well as necessary 25 expansion due to repeated cell divisions. However, whether cell division in HSCs precedes differentiation 26 is unclear. To this end, we used an HSC cell tracing approach and Ki67 RFP knock-in mice to assess 27 simultaneously divisional history, cell cycle progression, and differentiation of adult HSCs in vivo. Our 28 results reveal that HSCs are able to differentiate into restricted progenitors, especially common myeloid 29 progenitors, restricted megakaryocyte-erythroid progenitors (PreMEs) and pre-megakaryocyte progenitors 30 (PreMegs), without undergoing cell division and even before entering the S phase of the cell cycle. 31
Additionally, the phenotype of the undivided but differentiated progenitors correlated with expression of 32 lineage-specific genes that manifested as functional differences between HSCs and restricted progenitors. 33
Thus, HSC fate decisions appear to be uncoupled from physical cell division. Our results facilitate a better 34 understanding of the mechanisms that control fate decisions in hematopoietic cells. Our data, together with 35 currently understood to be a sequence (or even a continuum) of decision steps in which the multi-lineage 47 potential of the cells is sequentially lost [8] [9] [10] . Although many of these steps have been investigated in great 48 detail, the entire picture is still repeatedly challenged 6, 8, 9, [11] [12] [13] . HSC transition through the multipotent and 49 restricted progenitor stages is also accompanied by intense cell proliferation 3 . However, it is unclear 50 whether each fate decision step is associated with one or more division events, or if cell proliferation and 51 differentiation are independent processes. Further, if differentiation of HSCs does require cell division, the 52 phase of the cell cycle that is particularly important for this process is also currently unknown. The 53 dependence of cell-fate decisions on cell cycle progression was so far only shown in vitro for pluripotent 54 embryonic stem cells [14] [15] [16] [17] . However, a few reports point toward a functional connection between these two 55 processes in adult stem cells, such as neuronal stem cells 16, 18 . With regard to hematopoietic stem and 56 progenitor cells, characterization of the cell cycle itself is currently ongoing [19] [20] [21] [22] , and an understanding of 57 how HSC fate decisions relate to cell division and cell cycle progression is lacking 19 . 58
Therefore, we used in vivo cell tracing to simultaneously follow the divisional history and the initial 59 differentiation steps of HSCs. Our data reveal that HSCs are able to differentiate into restricted progenitors 60 prior to cell division, most prominently megakaryocyte-erythroid progenitors (PreME) and pre-61 megakaryocyte progenitors (PreMeg), and that this occurs before the cells enter the S phase of the cell 62 cycle. Moreover, our data also demonstrate that the G0/G1 phases are crucial for fate decision in HSCs to 63 either differentiate or self-renew. 64
65

Results
66
HSCs differentiate into myeloid progenitors in vivo without undergoing cell division 67
To study the initial steps of HSC differentiation in vivo, we sorted [24] [25] [26] . We used the CellTrace Violet dye 27, 28 to uniformly label HSCs and track cell-division history 70 after transplantation (Figure 1a) . Recently, Shimoto et al have shown that numerous empty HSC niches are 71 available upon transplantation into non-conditioned recipients, which are located distant from filled niches 72 and available for HSC engraftment and proliferation. Moreover, donor HSCs give rise to all blood cells 73 without any bias 29 . Labelled cells were transplanted into unconditioned recipients to prevent irradiation-74 induced stress [30] [31] [32] (Figure 1a ). Thirty-six hours after transplantation, 30% of the donor cells had 75 downregulated Sca-1 expression (Figure 1b) , one of the principal surface markers for HSCs 33 , and changed 76 their phenotype from HSCs to myeloid progenitors (MP). Importantly, the purification procedure alone did 77 not lead to down-regulation of Sca-1 (Supplementary Figure 1a) . A possible contamination of potential 78 donor MPs was excluded, since transplantation of these progenitors alone did not result in any detectable 79 donor MPs 36 hours later (Supplementary Figure 1b) . To further classify these phenotypically restricted 80
MPs in vivo, we used a previously described method of surface staining Figure 3a) 1 and 50% of the MPs remained undivided (Figure 1c) . Additionally, based on 92 CD41 and CD150 expression, these MPs were predominantly CMPs, PreMEs, and PreMegs (Figure 1d-e) . 93 as compared to the previous gating strategy (Supplementary Figure 1e) . To exclude the possibility that 96
HSCs differentiated into MPs without division due to the limited niche space, we used the HSC-97
CreERT+R26
DTA/DTA mouse line allowing for the inducible depletion of HSCs and transplanted CellTrace 98 dye labelled wild type HSCs into them 37 (Supplementary Figure 1f) . However, we did not find any 99 difference in the frequency of HSCs differentiated into myeloid restricted progenitors 36h after 100 transplantation, compared to controls ( Supplementary Figure 1g-h) . Surprisingly, compared to mice not 101 preconditioned with tamoxifen (TAM), we found that donor HSCs in TAM treated mice displayed enhanced 102 differentiation into GMPs without cell division, suggesting potentially additional stress induced by TAM. suggest that HSCs/MPPs can give rise to restricted progenitors including CMPs, PreMEs, and PreMegs 107 based on the cell phenotype, without undergoing cell division. 108
Phenotype of undivided differentiated progenitors correlates with expression of lineage-specific genes 109
To investigate the molecular differences between undivided HSCs and undivided MPs, we designed a panel 110 of primers to analyse single-cell expression levels of 70 genes including cell cycle genes and those specific 111 for HSCs, myeloid, erythroid, megakaryocyte-erythroid progenitors (MEP) and platelets (Supplementary 112 Table 1 ) 8, 9, 11, 12, 33, [38] [39] [40] [41] . Essentially, single-cell expression analysis of freshly sorted HSCs, CMPs, PreMEs 113 and PreMegs showed a clear separation of the cell types whether based on all analyzed genes or only on 114 selected MEP/Platelet genes ( Supplementary Figure 4a- 
c). 115
We then isolated undivided donor cells at 36h after transplantation of LSK CD48 -CD41 -CD150 + cells 116 While the cell tracing dye allowed us to follow cell division, it did not give information on cell cycle 138 progression. Therefore, to determine in which phase of the cell cycle HSCs make fate decisions, we scored 139 each cell for its likely cell cycle phase using signatures for G1, S/G2/M phases 39 . We categorized individual 140 cells in the G0/G1 or the S/G2/M phases (Figure 4a ) based on the average expression of phase specific 141 genes 39, 43 . As expected, and later confirmed by expression of individual cell cycle genes (Figure 4b ), HSCs 142 were more quiescent, with almost one-third of the PreME/PreMeg cells still in the G0/G1 phases ( Figure  143 4a). We also confirmed cluster separation between cells in G0/G1 and S/G2/M phases by performing t-SNEanalysis based on all 15 measured cell cycle genes but restricted to PreME/PreMeg populations (Figure 4c) . 145
Next, to determine if the expression of MEP/platelet genes is dependent on progression through the S/G2/M 146 phases, we again used t-SNE analysis to compare PreME/PreMeg cells in the G0/G1 and S/G2/M phases. 147
Remarkably, there was no separation of cells according to their cell cycle status (Figure 4c ), suggesting that 148 PreME/PreMeg cells had previously upregulated differentiation genes in the G0/G1 phases of the cell cycle. 149
That PreME and PreMeg cells increase expression of lineage specific genes independent of cell cycle phase, 150 was further supported by comparing the mean expression of MEP/Platelet genes between cells in G0/G1 151 and S/G2/M phases (Figure 4d ). Indeed, PreME and PreMeg cells increase expression of the lineage specific 152 genes independent of cell cycle phases. These data imply that transplanted HSCs differentiate before 153 entering the S phase of the cell cycle. 154
To corroborate these findings, we used the recently described Ki67 RFP knock-in mice 44 . KI67 is a nuclear 155 protein that is absent in the G0 phase, starts to be synthesized at the beginning of the S phase, increases 156 until mitosis, and gradually decreases thereafter in the G1 phase of the daughter cells until re-entry into the 157 To follow HSCs through cell cycle progression and differentiation, we sorted RFP -HSCs residing in the 163 G0/G1 phases, labeled them with CellTrace Violet, and transplanted these cells into non-conditioned 164 recipients. Our results reveal that the majority of donor undivided MPs did not upregulate RFP expression 165 (Figure 4e ), thus remaining in the G0/G1 phases. When taken together with the above results, these findings 166 demonstrate that HSCs do not require S phase entry to become phenotypic MPs. 167
Functional differences between undivided HSCs and progenitors
We used in vitro colony assays to verify functional differences between undivided phenotypic HSCs and 169 . Twelve days later, 89% of HSCs were 172 multipotent and gave rise to all cell types (myeloid, erythroid, and megakaryocyte), whereas 92% of the 173
PreMegs differentiated into megakaryocytes alone, clearly suggesting that this population had lost their 174 multipotency ( Figure 5a ). 175
We further investigated the in vivo repopulating capacity of donor cells. For this, we sorted undivided donor 176 In this study, we demonstrated in vivo that HSCs can differentiate into ST-HSCs, MPPs, and even restricted 185 myeloid progenitors, before undergoing cell division. Using a cell tracing approach and Ki67 RFP knock-in 186 mice, we followed HSC differentiation in vivo and analysed the expression of several essential 187 megakaryocyte-erythroid and myeloid specific genes, and cell-cycle genes, at the single-cell level. Our 188 findings using undivided PreMegs reveal that phenotypic and gene expression changes in undivided but 189 Indeed, the idea that cells can make fate decisions in the G1 phase of the cell cycle is not new. Pluripotent 211 stem cells (PSCs) initiate differentiation during progression through the G1 phase 14 due to the presence of 212 a 'window of opportunity', which is dependent on epigenetic changes that occur during that phase. On the 213 other hand, PSCs maintain their pluripotent state during the S and G2 phases of the cell cycle, which is 214 regulated by the cell cycle machinery but is independent of the G1 phase 
Materials and Methods
390
Mice. C57BL/6 (B6), B6.SJL-PtprcaPep3b/BoyJ (B6.SJL), HSC-CreERT/R-DTA and Ubc:GFP mice were 391 purchased from the Jackson Laboratory. Ki67 RFP knock-in mice have been described before 44 . All mice 392 were bred and maintained under specific pathogen-free conditions in the animal facility at the Medical 393
Theoretical Center of the University of Technology, Dresden. Experiments were performed in accordance 394 with the German animal welfare legislation and were approved by local authorities. 395
Cre-activation. One week before the start of TAM administration, mice were kept on low phytoestrogen 396 standard diet (LASvendi, Solingen, Germany). 30 mg tamoxifen tablets (Ratiopharm, Ulm, Germany) were 397 dissolved overnight in lipid emulsion (SMOFlipid, Fresenius Kabi, Bad Homburg, Germany). 20 mg/ml 398 tamoxifen solution was applied two times (72h apart) by oral gavage at a dose of 0.2mg / g body weight to 399 animals at the age of 8 -14 weeks. 400
Transplantation. Bone marrow was isolated from mouse tibia, femora, pelvis, and vertebrae, crushed, and 401 filtered through a 70-µm cell strainer. Cells were lysed in ACK Lysis Buffer (Life technologies at. A10492-402 01), and lineage depleted using biotinylated antibodies (anti-mouse CD3 (2C11; 17A2), CD11b (M1/70), 403 CD19 (1D3), CD45R (RA3-6B2), Gr-1 (RB6-8C5), Nk1.1 (PK136)) and anti-biotin micro-beads using 404 magnetic cell separation Cytospins. Cells were spun onto object slides at 500 RPM, dried and stained with May-Grunwald and 427
Gimza solution (Sigma Aldrich). 428
In vitro culture. Single cells were sorted and cultured in 96 well plates in StemSpan SFEM medium 429 (STEMCELL Technologies, Cat. 09600) supplemented with 20 ng/ml rmSCF (Peprotech, 250-03), 20 430 ng/ml rmTpo (eBioscince, 34-8686-63), 20 ng/ml rmIl3 (Peprotech, 213-13), and 5 U/ml rhEpo (Roche), 431 and cultivated for 12 days at 37 0 C with 5% CO2. 432
Cell cycle analyses. For intracellular staining, cells were fixed and permeabilized using fixation and 433 permeabilization buffers from eBioscience. To distinguish between the G0 and G1 phase, cells were stained 434 for intracellular Ki-67 FITC (eBiosciences, clone SolA15). DAPI (4, 6 diamidino-2-phenylindole; 435 Molecular Probes) was used to measure DNA content and separate the cells in S/G2/M phases from those 436 in the G0 and G1 phase. For the BrdU incorporation assay, 10µM BrdU (Sigma-Aldrich) was added to the 437 culture for 3.5 h and BrdU incorporation analyses performed as described previously 46 using anti-BrdU-438 FITC ab (eBioscience, clone BU20a).
Clustering based analysis of cell cycle state. Cell cycle genes were classified based on single cell deep 440 sequencing data 39 or defined previously in synchronized HeLa cells 43 (G1 phase genes: Ccne1, Cdk2, 441 Cdkn1a, Cdkn1c, S/G2/M phase genes: Cdkn2d, E2f4, Cdk6, Cdkn2c, Ccng2, Ccnf, Mki67, Ccna2, Ccnb1, 442 Ccnb2, Cdc20). First, expression of each gene for each cell was normalized to the maximum expression of 443 the gene; second, cell cycle signature for each cell was defined as the average expression of phase specific 444 subsets of cell cycle genes. Discrimination between G1 and S/G2/M was done based on the distribution of 445 control HSCs (before transplantation) and data that around 90% of HSCs (mouse strain C57Bl6) are in 446 G0/G1 phase of the cell cycle. 447
Single-cell qPCR. Gene expression profiles of single cells were obtained as previously described 54, 55 but 448 with modifications. cDNA was synthesized directly on the cells using the Quanta qScript TM cDNA 449 Supermix. Total cDNA was pre-amplified for 20 cycles (1x 95ºC 5', 95ºC 45'', 60ºC, 1', 72ºC 1.5') and 450 once at 68ºC for 10' using the Multiplex PCR Kit (Qiagen, Hilden, Germany) in a final volume of 35 µl in 451 the presence of primer pairs (25nM for each primer) for all genes (listed in Table S1 ). Pre-amplified cDNA 452 Representative plots and pictures from 2 independent experiments (n=5). We checked the mice every 3-4 531 weeks for a period of 16 weeks after transplantation, but did not find any repopulation from MPs. M e g M y e l
